For those desiring to outshine the market, the strategic selection of individual stocks is paramount. Well-chosen stocks have the potential to substantially boost your wealth.
The price of Viking Therapeutics Inc (NASDAQ: VKTX) closed at $29.20 in the last session, down -14.29% from day before closing price of $34.07. In other words, the price has decreased by -$14.29 from its previous closing price. On the day, 8.91 million shares were traded.
Ratios:
We take a closer look at VKTX’s different ratios to gain a better understanding of the stock. For the most recent quarter (mrq), Quick Ratio is recorded 36.47 and its Current Ratio is at 33.09. In the meantime, Its Debt-to-Equity ratio is 0.00 whereas as Long-Term Debt/Eq ratio is at 0.00.
Upgrades & Downgrades
In addition, analysts’ ratings and any changes thereto give investors an idea of the stock’s future direction. In the most recent recommendation for this company, Scotiabank on February 13, 2025, initiated with a Sector Outperform rating and assigned the stock a target price of $102.
On February 07, 2025, Citigroup started tracking the stock assigning a Neutral rating and target price of $38.
Insider Transactions:
An investor can also benefit from insider trades by learning what management is thinking about the future direction of stock prices. A recent insider transaction in this stock occurred on Jan 06 ’25 when Lian Brian sold 194,490 shares for $42.75 per share. The transaction valued at 8,313,601 led to the insider holds 2,366,570 shares of the business.
Mancini Marianna sold 54,215 shares of VKTX for $2,317,599 on Jan 06 ’25. The Chief Operating Officer now owns 374,134 shares after completing the transaction at $42.75 per share. On Jan 06 ’25, another insider, ZANTE GREG, who serves as the Chief Financial Officer of the company, sold 50,309 shares for $42.75 each. As a result, the insider received 2,150,595 and left with 165,259 shares of the company.
Stock Price History:
Over the past 52 weeks, VKTX has reached a high of $99.41, while it has fallen to a 52-week low of $28.64. The 50-Day Moving Average of the stock is -21.03%, while the 200-Day Moving Average is calculated to be -46.18%.
Shares Statistics:
A total of 111.57M shares are outstanding, with a floating share count of 108.14M. Insiders hold about 2.96% of the company’s shares, while institutions hold 74.25% stake in the company.
Earnings Estimates
Viking Therapeutics Inc (VKTX) is presently subject to a detailed evaluation by 11.0 analysts, each offering their unique perspectives on its market standing.The consensus estimate for the next quarter is -$0.36, with high estimates of -$0.19 and low estimates of -$0.43.
Analysts are recommending an EPS of between -$0.98 and -$2.16 for the fiscal current year, implying an average EPS of -$1.55. EPS for the following year is -$2.12, with 14.0 analysts recommending between -$1.4 and -$3.1.
